Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption
Open Access
- 15 September 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (6) , 897-900
- https://doi.org/10.1086/432887
Abstract
Forty-five human immunodeficiency virus (HIV)—infected patients stopped taking treatment but resumed taking it thereafter. All 11 who resumed treatment with their prior protease inhibitor (PI)—based regimen reattained an undetectable virus load, whereas this occurred for only 15 (44%) of 34 patients who resumed nonnucleoside reverse-transcriptase inhibitor (NNRTI)—based treatment (P < .001). Distinct pharmacokinetics and resistance barriers may result in different performances for PIs and NNRTIs after treatment interruptions.Keywords
This publication has 10 references indexed in Scilit:
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 2003
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 2003
- Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptionsAIDS, 2002
- Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosidesAIDS, 2002
- Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by Nevirapine in Patients With Suppressed Plasma HIV-1 RNAJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmissionAIDS, 2000
- Meta-analysis of Two Randomized Controlled Trials Comparing Combined Zidovudine and Didanosine Therapy With Combined Zidovudine, Didanosine, and Nevirapine Therapy in Patients With HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Higher antiviral activity of antiretroviral regimens including protease inhibitorsAIDS, 1999
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- Kinetic Characterization and Cross-Resistance Patterns Of HIV-1 Protease Mutants Selected under Drug PressureBiochemistry, 1995